Overbought Stocks — Overview View · Pharmaceutical Preparations
30 stocks match the Overbought Stocks screen. Stocks with an RSI (14) above 70 — technically overbought, most-overbought first. Overview columns. Filtered to Pharmaceutical Preparations. Data as of close · Checked
| PCRX | Pacira Biosciences, Inc. | Healthcare | Pharmaceutical Preparations | $1.5B | 99.19 | 36.42 | +0.10% | Bullish | 165K |
| VRDN | Viridian Therapeutics, Inc.De | Healthcare | Pharmaceutical Preparations | $3.3B | -7.27 | 29.05 | +15.62% | Bullish | 819K |
| RDY | Dr Reddys Laboratories Ltd | Healthcare | Pharmaceutical Preparations | — | — | 14.77 | +3.18% | Bullish | 248K |
| INM | InMed Pharmaceuticals Inc. | Healthcare | Pharmaceutical Preparations | $10M | -0.75 | 1.80 | +6.82% | Bullish | 1K |
| LYEL | Lyell Immunopharma, Inc. | Healthcare | Pharmaceutical Preparations | $380M | -1.49 | 15.47 | +42.98% | Bearish | 53K |
| KRRO | Korro Bio, Inc. | Healthcare | Pharmaceutical Preparations | $244M | -2.29 | 16.59 | +4.73% | Bullish | 9K |
| XNCR | Xencor Inc | Healthcare | Pharmaceutical Preparations | $2.6B | -22.30 | 35.03 | +14.33% | Bullish | 113K |
| SLN | Silence Therapeutics Plc | Healthcare | Pharmaceutical Preparations | $2.8B | -46.79 | 19.79 | +0.00% | Bullish | 70K |
| LKFT | Lakefront Biotherapeutics Nv | Healthcare | Pharmaceutical Preparations | — | — | 34.10 | +6.07% | Bullish | 27K |
| ZTS | Zoetis | Healthcare | Pharmaceutical Preparations | $36.8B | 14.08 | 89.16 | +7.40% | Bearish | 347K |
| SNY | Sanofi | Healthcare | Pharmaceutical Preparations | — | — | 47.44 | +4.65% | Bullish | 446K |
| GMAB | Genmab A/S | Healthcare | Pharmaceutical Preparations | — | — | 55.08 | -0.74% | Strongly Bullish | 328K |
| LLY | Lilly (Eli) | Healthcare | Pharmaceutical Preparations | $1.33T | 48.37 | 1418.07 | +0.62% | Bullish | 192K |
| GRFS | Grifols Sa | Healthcare | Pharmaceutical Preparations | — | — | 8.60 | +0.53% | Bullish | 52K |
| DMAC | DiaMedica Therapeutics Inc. | Healthcare | Pharmaceutical Preparations | $582M | -15.50 | 10.79 | +7.68% | Bullish | 30K |
| RPRX | Royalty Pharma Plc | Healthcare | Pharmaceutical Preparations | $30.1B | 44.80 | 67.56 | +1.82% | Bullish | 202K |
| ABT | Abbott Laboratories | Healthcare | Pharmaceutical Preparations | $200.2B | 42.58 | 115.57 | +5.61% | Bullish | 933K |
| PHAR | Pharming Group N.V. | Healthcare | Pharmaceutical Preparations | — | — | 12.92 | +0.31% | Bearish | 29 |
| BBIO | Bridgebio Pharma, Inc. | Healthcare | Pharmaceutical Preparations | $15.2B | -20.72 | 77.97 | +5.36% | Bullish | 383K |
| AZN | Astrazeneca Plc | Healthcare | Pharmaceutical Preparations | — | — | 189.00 | +2.77% | Bullish | 352K |
| TRAX | First Tracks Biotherapeutics, Inc. | Healthcare | Pharmaceutical Preparations | $2.1B | — | 49.13 | +5.93% | Bullish | 74K |
| SEPN | Septerna, Inc. | Healthcare | Pharmaceutical Preparations | $2.2B | -92.21 | 47.88 | +9.47% | Bullish | 57K |
| BHC | Bausch Health Companies Inc. | Healthcare | Pharmaceutical Preparations | $3.1B | -3.71 | 8.34 | +2.58% | Strongly Bullish | 253K |
| UTHR | United Therapeutics Corp | Healthcare | Pharmaceutical Preparations | $25.9B | 21.02 | 607.43 | +0.95% | Bullish | 68K |
| TAK | Takeda Pharmaceutical Co Ltd | Healthcare | Pharmaceutical Preparations | — | — | 21.07 | +1.47% | Bullish | 205K |
| ZYME | Zymeworks Inc. | Healthcare | Pharmaceutical Preparations | $2.2B | -14.64 | 30.94 | +2.69% | Bullish | 40K |
| ELAN | Elanco Animal Health Inc | Healthcare | Pharmaceutical Preparations | $12.6B | -63.54 | 25.31 | +2.97% | Bullish | 920K |
| NVS | Novartis Ag | Healthcare | Pharmaceutical Preparations | — | — | 165.02 | +3.64% | Bullish | 116K |
| ORKA | Oruka Therapeutics, Inc. | Healthcare | Pharmaceutical Preparations | $6.7B | -50.56 | 101.48 | +1.85% | Bullish | 40K |
| PVLA | Palvella Therapeutics, Inc. | Healthcare | Pharmaceutical Preparations | $2.3B | -37.99 | 162.66 | +6.31% | Bullish | 34K |
Source: SEC EDGAR/XBRL (fundamentals, shares) · Databento EQUS.MINI (EOD prices) · multiples, ratios & technicals computed by tradmap. Financials: Trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year; revenue is the fiscal-year figure where quarterly revenue covers under half of it (typical for banks, insurers and REITs), and margins are taken on it. A company reporting in another currency is shown in ≈ USD: its figures convert at the Federal Reserve H.10 rate of its price date (FRED), and without a rate its multiples are blank. This product uses the FRED® API but is not endorsed or certified by the Federal Reserve Bank of St. Louis. Informational only — not financial advice.